PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ESKIMOS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 361 records · Page 20Linked to original sources
PubMed1975

Twenty-four hour urinary excretion of vitamins, minerals and nitrogen by Eskimos.

In 1971-1972, urines were collected over 24 hours from ambulatory Iglooligmiut who ranged in age from 6 to 76 years. Collections were made every 3-4 months over a calendar year. The mean of each individual's two to four collections was used as the best estimate of that person's average daily excretion for nitrogen, thiamin, riboflavin, N'-methylnicotinamide, calcium, phosphorus, and magnesium. The excretion of the three B vitamins by all age groups was high when compared with interpretive standards. Urea nitrogen comprised 80-90% of total nitrogen excreted by all age groups. Twenty-four-hour mineral excretions did not differ with age and sex group except that adult men excreted significantly more phosphorus. Urinary urea nitrogen and phosphorus were linearly related, suggesting that they have a common source; namely, meat. Winter was generally the season of lowest excretion of the nutrients assayed. Since these nutrients are available from imported foods, particularly during the winter, it would appear that even in the winter the Iglooligmiut are more dependent on hunting and fishing for sources of these nutrients than on the well-stocked commercial grocery outlets.

Adolescent↗
PubMed1992

Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos.

Evidence that the larval stage of Echinococcus multilocularis in humans is killed by chemotherapy is presented in a review of our 17-year experience with treatment of alveolar hydatid disease in Alaska. The efficacy of chemotherapy was assessed with use of an in vivo assay of parasite viability by means of inoculation of voles, immunohistochemical tests, and histopathologic findings. Of 14 tests performed for nine patients, 12 in vivo assays (86%) were negative after chemotherapy, while only two (17%) of 12 vole tests for seven untreated patients were negative. Regression of arrest of growth of metastatic and primary hepatic lesions, together with their partial-to-complete calcification and prolonged survival times has been observed among patients treated with the benzimidazole compounds. For six who received appropriate chemotherapy, treatment has been discontinued for an average of 4.6 years (range, 3-7 years) without an increase lesion size or other evidence of reactivation.

Adult↗
PubMed1997

Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study.

A hepatitis B virus vaccine demonstration project was conducted in southwest Alaska in 1981-1982 to determine the immunogenicity and efficacy of the vaccine. A total of 1630 susceptible persons in the Alaskan Native population were vaccinated with the recommended three-dose regimen of plasma-derived hepatitis B vaccine, and 94% demonstrated antibody to hepatitis B surface antigen (anti-HBs) at levels > or = 10 mIU/mL. After 10 years of follow-up, 76% of those immunized had anti-HBs levels > or = 10 mIU. During the 10 years following the first dose of vaccine, 13 study participants developed antibody to hepatitis B core antigen (10 vaccine responders, 3 nonresponders), and none developed sustained HBs positivity or had clinical hepatitis. These data suggest that immunization with hepatitis B vaccine continues to provide high levels of protection from clinical disease for at least 10 years.

Adolescent↗